Immunovant Inc (NAS:IMVT)

$ 27.32 0.03 (0.11%) Market Cap: 3.99 Bil Enterprise Value: 3.35 Bil PE Ratio: 0 PB Ratio: 6.44 GF Score: 42/100

Immunovant Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Immunovant Inc To Discuss Portfolio Update Call Transcript
Nov 28, 2023
Immunovant Inc Initial Phase 1 Results Call Transcript
Sep 26, 2023
Immunovant Inc Fireside Chat Hosted by LifeSci Capital Transcript
Dec 08, 2022
Immunovant Inc Investor Day Transcript
Sep 28, 2022
Immunovant Inc To Discuss On Two New Indications For Batoclimab Call Transcript
Sep 07, 2022
Q4 2022 Immunovant Inc Earnings Call Transcript
Jun 08, 2022

$3.92 (-8.20%)

Earnings
Immunovant Inc at UBS Global Healthcare Conference Transcript
May 23, 2022
Immunovant Inc To Host R&D Day (Virtual) Transcript
Mar 30, 2022
Immunovant Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call Transcript
Jan 05, 2022
Immunovant Inc at Stifel Healthcare Conference (Virtual) Transcript
Nov 17, 2021
Immunovant Inc at Roivant R&D Day (Virtual) Transcript
Sep 28, 2021
Q1 2022 Immunovant Inc Earnings Call Transcript
Aug 09, 2021

$7.78 (+0.39%)

Earnings
Q4 2021 Immunovant Inc Earnings Call Transcript
Jun 01, 2021

$9.4 (-37.99%)

Earnings
Immunovant, Inc. - Special Call Transcript
Feb 02, 2021
Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 12, 2020
Immunovant, Inc. - Special Call Transcript
Aug 25, 2020
Immunovant Inc Annual Shareholders Meeting Transcript
Aug 19, 2020
Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update Transcript
Mar 30, 2020

Immunovant Inc Initial Phase 1 Results Call Transcript

Sep 26, 2023 / 12:00PM GMT

Release Date Price: $39.96 (+97.04%)

Transcript

Operator

Good morning. My name is Michelle, and I'm your conference call operator. As a reminder, this call is being recorded. Before we begin, I would like to remind everyone that today's conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, for example, statements regarding the potential efficacy and safety of Immunovant's product candidates and Immunovant's expectations regarding the timing, design and results of its clinical trials, including the timing of future data readouts and the announcement of future indications.

These forward-looking statements are not guarantees of future performance and are subject to various risks, events and uncertainties, assumptions known or unknown, which could cause actual results to vary materially from those indicated or anticipated. For more information, investors are encouraged to review Immunovant's most recent quarterly report on Form 10-Q filed with the SEC on August 10, 2023. Joining me on the call this morning is Dr. Peter Salzmann, Chief

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.